With these advances, we hope to see the Bi-ChTCRs move to the clinic, hoping to generate long-lasting responses and prevent relapses in cancer patients.

@fredhutch.bsky.social
#CancerResearch #Immunotherapy #TCellTherapy #Bi-ChTCR #SyntheticImmunity

With these advances, we hope to see the Bi-ChTCRs move to the clinic, hoping to generate long-lasting responses and prevent relapses in patients.
@fredhutch.bsky.social @natureportfolio.nature.com @naturecancer.bsky.social
#CancerResearch #Immunotherapy #TCellTherapy #BiChTCR #SyntheticImmunity